KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) Invested Capital (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Invested Capital for 13 consecutive years, with $581.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Invested Capital fell 22.94% to $581.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $581.8 million, a 22.94% decrease, with the full-year FY2025 number at $581.8 million, down 22.94% from a year prior.
  • Invested Capital was $581.8 million for Q4 2025 at Xenon Pharmaceuticals, up from $559.5 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $927.9 million in Q4 2023 to a low of $248.9 million in Q3 2021.
  • A 5-year average of $639.8 million and a median of $666.7 million in 2023 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: skyrocketed 220.99% in 2021, then decreased 29.87% in 2025.
  • Xenon Pharmaceuticals' Invested Capital stood at $550.0 million in 2021, then soared by 31.17% to $721.5 million in 2022, then increased by 28.61% to $927.9 million in 2023, then dropped by 18.65% to $754.9 million in 2024, then dropped by 22.94% to $581.8 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Invested Capital are $581.8 million (Q4 2025), $559.5 million (Q3 2025), and $634.0 million (Q2 2025).